ESMO 2025: VT3989 Demonstrates Promising Early Outcomes in Advanced Mesothelioma Patients
In a groundbreaking advancement in oncology, researchers from The University of Texas MD Anderson Cancer Center have unveiled promising results from clinical trials of VT3989,...
















